<PAGE>
Cytomedix Completes Acquisition of Procuren From Curative; 1/2/1 13:54 (New
York)
Company Expands Cellular Therapy Portfolio
Business Editors, Health/Medical Writers
DEERFIELD, Ill.--(BUSINESS WIRE)--Jan. 2, 2001--Cytomedix, Inc. (OTC BB:
CYDX.OB) and its affiliates today announced that it has completed the
acquisition of the worldwide manufacturing, sales and distribution rights to
Procuren(R) solution, a proprietary wound-healing agent, from Curative Health
Services, Inc. (NASDAQ: CURE) for $3.8 million. The Procuren acquisition expands
Cytomedix's product portfolio, which includes AuTolo-Gel(TM), its proprietary
system for the treatment of non-healing wounds.
"With the closing of the acquisition of Procuren, we have moved our
business forward. We're committed to building a robust cellular therapy
portfolio," said James A. Cour, president and chief executive officer,
Cytomedix, Inc. "This acquisition enables us to offer our customers two
therapeutic options for chronic wound care and expand our distribution channels
for AuTolo-Gel."
Procuren is currently distributed exclusively in the U.S. through the
more than 130 clinics managed by Curative Health Services. AuTolo-Gel will also
be made available to Curative's clinics on a non-exclusive basis. Cytomedix will
market both AuTolo-Gel and Procuren outside the United States. Cytomedix will
assume responsibility for 34 processing facilities located throughout the United
States.
About Cytomedix, Inc.: Cytomedix is engaged in the development and sale
of cellular therapies and molecular biotechnology products for the treatment of
disease. The company licenses its AuTolo-Gel process to hospitals and clinics
for the treatment of chronic wounds such as diabetic foot, venous statis and
pressure ulcers.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such forward
looking statements involve known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or achievements of
Cytomedix Inc. (The Company) or industry results to be expressed or implied by
such forward looking statements.
Readers of this press release may obtain additional information on The
Company in reports and other information filed in accordance with the Securities
Exchange Act of 1934, as amended (the "Exchange Act"). Such reports and other
information filed by The Company can be inspected and copied at the public
reference facilities maintained by the Commission at the Public Reference Room,
450 Fifth Street, N.W., Washington, DC 20549.
<PAGE>
Copies of such material can also be obtained at prescribed rates from
the Public Reference Section of the Commission, Washington, DC, 20549 or by
calling the Commission at 1-800-SEC-0330.
In addition, Registration Statements and other filings made with the
Commission through its Electronic Data Gathering Analysis and Retrieval System
("EDGAR") and publicly available through the Commission's website located at
http://www.sec.gov.
--30--SB/na*
CONTACT: Fleishman Hillard Inc.
Laurel Green, 312/751-3626
[email protected]
